Contents

Monthly Volume 12 Number 12 December 27, 2020

REVIEW

468 Carbohydrate antigen 19-9 — tumor marker: Past, present, and future

Lee T, Teng TZJ, Shelat VG

ORIGINAL ARTICLE

Retrospective Study

491 Partial pancreatic tail preserving subtotal pancreatectomy for pancreatic cancer: Improving glycemic control and quality of life without compromising oncological outcomes

You L, Yao L, Mao YS, Zou CF, Jin C, Fu DL

507 Risk factors for postoperative stoma outlet obstruction in ulcerative colitis

Kitahara T, Sato Y, Oshiro T, Matsunaga R, Nagashima M, Okazumi S

Clinical Trials Study

520 Liver transplant for large hepatocellular carcinoma in Malatya: The role of gamma glutamyl transferase and alpha-fetoprotein, a retrospective cohort study


SYSTEMATIC REVIEWS

534 Ectopic liver tissue (choristoma) on the gallbladder: A comprehensive literature review


CASE REPORT

549 Giant simple hepatic cyst with multiple elevated serum tumor markers: A case report

Zhang JW, Peng C, Ye YS, Li W

555 Individualized treatment for gastric cancer with rib metastasis: A case report

Zhang Y, Zhang ZX, Lu ZX, Liu F, Hu GY, Tao F, Ye MF
ABOUT COVER
Associate editor of World Journal of Gastrointestinal Surgery, Dr. Vishal G Shelat is a Senior Consultant Surgeon at Tan Tock Seng Hospital, Singapore. Having received his Bachelor’s degree from Gujarat University (Ahmedabad, India) in 2000, Dr. Shelat undertook his postgraduate training first at B.J. Medical College and Civil Hospital (Ahmedabad, India), receiving his Master’s degree in 2003, and then at the National University of Singapore, receiving his MD (General Surgery) in 2008. He became Consultant Surgeon in the Department of Surgery at Tan Tock Seng Hospital in 2014. His research interests include the application of evidence-based medicine in digestive diseases, particularly to study the effects of such integrative medicine methods on and management of disease-syndrome pattern establishment. Currently, he serves as member of the Chapter of General Surgery, College of Surgeons of Singapore and Treasurer for the Singapore Hepatopancreatobiliary Association. (L-Editor: Filipodia)

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Surgery (WJGS, World J Gastrointest Surg) is to provide scholars and readers from various fields of gastrointestinal surgery with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGS mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal surgery and covering a wide range of topics including biliary tract surgical procedures, biliopancreatic diversion, colectomy, esophagectomy, esophagostomy, pancreas transplantation, and pancreatectomy, etc.

INDEXING/ABSTRACTING
The WJGS is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, and PubMed Central. The 2020 edition of Journal Citation Reports® cites the 2019 impact factor (IF) for WJGS as 1.863; IF without journal self cites: 1.824; Ranking: 109 among 210 journals in surgery; Quartile category: Q3; Ranking: 77 among 88 journals in gastroenterology and hepatology; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Jia-Hui Li; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

NAME OF JOURNAL
World Journal of Gastrointestinal Surgery

ISSN
ISSN 1948-9366 (online)

LAUNCH DATE
November 30, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Shu-You Peng, Varut Lohsiriwat, Jin Gu

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
December 27, 2020

COPYRIGHT
© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.tifpublishing.com

© 2020 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com
CASE REPORT

Giant simple hepatic cyst with multiple elevated serum tumor markers: A case report

Jia-Wei Zhang, Cheng Peng, Yan-Shuo Ye, Wei Li

ORCID number: Jia-Wei Zhang 0000-0003-1107-4948; Cheng Peng 0000-0002-5338-5325; Yan-Shuo Ye 0000-0002-7884-9659; Wei Li 0000-0001-7917-7666.

Author contributions: Zhang JW initially identified the case, collected and organized the medical records, and performed an intensive revision of the manuscript; Peng C primarily drafted the article, accomplished the actual writing, selected the references, and drafted the discussion; Ye YS also performed the revision of the manuscript; Li W contributed to the conceptual design, and carried out critical revision and finalization of the manuscript.

Supported by Nature Science Foundation of The Science and Technology Bureau of Jilin Province, No. Li 2019020127JC; and The Innovation Capacity Building Fund of The Development and Reform Commission of Jilin Province, No. Li 2019C015.

Informed consent statement: The patient provided informed written consent for the publication of this case report.

Conflict-of-interest statement: None.

Abstract

BACKGROUND

Simple hepatic cysts are relatively common in adults, and mostly appear as asymptomatic incidental radiologic findings. Occasionally, a large cyst will cause symptoms. Elevations in the serum biomarkers protein induced by vitamin K absence (PIVKA)-II, cancer antigen (CA) 12-5, and CA19-9 are often associated with malignant tumors in the liver or bile ducts. This is the first report to describe a case of hepatic cyst with elevated levels of PIVKA-II and CA12-5.

CASE SUMMARY

An 84-year-old Chinese woman was admitted with gradual abdominal distension. Her symptoms started 1 year ago, and she had poor appetite and a weight loss of 5 kg within the past 2 wk. She denied any symptoms associated with abdominal pain, fever and chills, nausea and vomiting, etc. The abdomen was enlarged, more in the right upper quadrant, without tenderness. Laboratory examination showed significantly increased serum levels of PIVKA-II, CA12-5, and CA19-9. A computed tomography scan revealed multiple round cysts in the liver with clear boundaries. The largest cyst was 20.1 cm × 12.2 cm × 19.6 cm in size, located in the right lobe of the liver with mild dilatation of the intrahepatic bile duct, but there was no contrast enhancement. Percutaneous drainage on the largest hepatic cyst and polycinnamol sclerosing agent injection into the cyst cavity were performed. After treatment, the patient’s symptoms relieved and the elevated serum tumor markers reduced to the normal levels dramatically.

CONCLUSION
The present report identifies an unusual case of a giant hepatic cyst with marked elevation of serum tumor marker levels of PIVKA-II, CA12-5, and CA19-9. After treatment, these three serum markers dramatically decreased to normal levels. The mechanisms for the elevation of these tumor markers may be as follows: (1) A giant hepatic cyst compresses the liver, causing injury to the hepatocytes, which may lead to secretion of a large amount of PIVKA-II; and (2) Some tumor-associated antigens, such as carcinoembryonic antigen, CA19-9, CA12-5, and CA15-3, are expressed on inflammatory cells.

**Key Words:** Hepatic cyst; Tumor markers; Protein induced by vitamin K absence-II; Cancer antigen 12-5; Cancer antigen 19-9; Case report

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Simple hepatic cysts typically appear as asymptomatic benign tumors of the liver without elevation of any diagnostic serum biomarkers. However, over the years, a few cases of simple hepatic cysts with elevated tumor markers have been reported in the world. Here, we report a case of giant simple hepatic cyst with elevation of multiple serum cancer biomarkers, including protein induced by vitamin K absence-II, cancer antigen (CA) 12-5, and CA19-9.

**Citation:** Zhang JW, Peng C, Ye YS, Li W. Giant simple hepatic cyst with multiple elevated serum tumor markers: A case report. *World J Gastrointest Surg* 2020; 12(12): 549-554

**URL:** https://www.wjgnet.com/1948-9366/full/v12/i12/549.htm

**DOI:** https://dx.doi.org/10.4240/wjgs.v12.i12.549

**INTRODUCTION**

Simple hepatic cysts are generally regarded as congenital malformations. This is a relatively common finding in adults, with a reported incidence ranging from 3.5% to 10% [1]. These cysts are usually small in size with abdominal symptoms occurring in less than 20% of the patients. Complications such as mass effect, rupture, hemorrhage, obstructive jaundice, and infection are rare, but may lead to the emergence of symptoms [2]. Overall, simple hepatic cysts are benign and lack serum biomarkers for diagnosis. A giant simple hepatic cyst is uncommon [3,4]. Serum protein induced by vitamin K absence (PIVKA)-II, cancer antigen (CA) 12-5, and cancer antigen CA19-9 are recognized as biomarkers for malignant tumor. These biomarkers are associated with hepatocellular carcinoma and bile duct carcinoma. Here, we report a rare case of giant simple hepatic cyst with marked elevation of serum PIVKA-II, CA12-5, and CA19-9 levels. We have found only one previous report of hepatic cyst with elevation of serum CA19-9 [5]. To the best of our knowledge, the present report is the first to describe a case of giant simple hepatic cyst with elevated serum cancer biomarker levels of PIVKA-II, CA12-5, and CA19-9.

**CASE PRESENTATION**

**Chief complaints**

An 84-year-old Chinese woman was admitted with gradual abdominal distension.

**History of present illness**

The patient’s symptoms started 1 year ago. And she had poor appetite and a weight loss of 5 kg within the past 2 wk. She denied any symptoms associated with abdominal pain, fever and chills, nausea and vomiting, etc.

**History of past illness**

There was no prior history of trauma, hepatitis, allergy, or alcohol or tobacco usage.
Personal and family history
No special.

Physical examination
Physical examination showed that she was in medium nutritional status with an icteric appearance. Vital signs were within normal ranges. The abdomen was asymmetrically enlarged, more in the right upper quadrant, without tenderness. Bowel movements occurred about 3-4 times per minute.

Laboratory examinations
Laboratory examination showed significantly increased serum levels of PIVKA-II (>30000 mAU/mL; reference: <32 mAU/mL), CA12-5 (428 U/mL; reference: <35 U/mL), and CA19-9 (51.67 U/mL; reference: <39 U/mL). Serum aspartate aminotransferase (AST) (97.03 IU/L; reference: <40 IU/L), alanine aminotransferase (ALT) (64.73 IU/L; reference: <40 IU/L), total bilirubin (TBIL) (61.19 µmol/L; reference: <21 µmol/L), and direct bilirubin (DBIL) (36.42 µmol/L; reference: <3.4 µmol/L) levels were moderately increased. Serum prothrombin time (PT) (33.3 s; reference: 11.0-15.0 s) and activated partial thromboplastin time (aPTT) (54.0 s; reference: 28.0-43.5 s) levels were also elevated slightly. However, serum albumin (ALB) (23.88 g/L; reference: >35 g/L), prealbumin (PLAB) (17.3 mg/L; reference: 180-390 mg/L), and choline esterase (CHE) levels (1750 IU/L; reference: 3000-13000 IU/L) were significantly low.

Imaging examinations
Following an initial abdominal ultrasound examination, an enhanced computed tomography (CT) scan was performed, which revealed multiple round cysts in the liver with clear boundaries. The largest cyst was located in the right lobe of the liver, with mild dilatation of the intrahepatic bile duct, and a size of approximately 20.1 cm × 12.2 cm × 19.6 cm. There was no contrast enhancement in either the arterial or venous phase (Figure 1).

FINAL DIAGNOSIS
Taking into account all of the patient’s symptoms, signs, and radiology examinations, a clinical diagnosis of simple hepatic cyst was established.

TREATMENT
We performed percutaneous drainage on the largest hepatic cyst and injected polycinnamol sclerosing agent into the cyst cavity. Approximately 1150 mL of yellowish green liquid was drained the first day. The cystic fluid was examined, with the results showing some inflammatory cells, but no bacteria, neoplastic cells, or parasites.

OUTCOME AND FOLLOW-UP
After 1 wk of drainage, the patient's symptoms of abdominal distension and early satiety were gradually eased. Follow-up at 2 mo post cyst drainage found that the size of the cyst had been much reduced, from 20.1 cm × 19.6 cm to 8.7 cm × 6.1 cm (Figure 2), and the serum tests for liver function, coagulating function, PIVKA-II, and CA19-9 revealed that the levels were restored to normal ranges. The serum CA12-5 level remained slightly higher (84.5 U/mL; reference: <35 U/mL) than normal, but it was significantly reduced from the previous level of 428 U/mL (Table 1).

DISCUSSION
Simple hepatic cysts are typically asymptomatic benign tumors of the liver. These cysts usually contain serous fluid, do not communicate with the biliary tree, and do not have separations. PIVKA II, also known as des-gamma-carboxy prothrombin
Table 1 Differences of the parameters post cyst drainage

<table>
<thead>
<tr>
<th></th>
<th>Before drainage</th>
<th>After drainage</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size of the cyst</td>
<td>20.1 cm × 19.6 cm</td>
<td>8.7 cm × 6.1 cm</td>
<td></td>
</tr>
<tr>
<td>PIVKA-II</td>
<td>&gt; 30000 mAU/mL</td>
<td>Normal</td>
<td>&lt; 32 mAU/mL</td>
</tr>
<tr>
<td>CA12-5</td>
<td>428 U/mL</td>
<td>84.5 U/mL</td>
<td>&lt; 35 U/mL</td>
</tr>
<tr>
<td>CA19-9</td>
<td>51.67 U/mL</td>
<td>Normal</td>
<td>&lt; 39 U/mL</td>
</tr>
</tbody>
</table>

(DCP), is an abnormal prothrombin molecule that is increased in malignant liver disease. During the malignant transformation of hepatocytes, the vitamin K-dependent carboxylase system becomes impaired, which leads to the production of PIVKA II\(^6,7\). CA12-5, which is derived from the coelomic epithelium including the endometrium, fallopian tubes, ovaries, and peritoneum, is commonly used for the diagnosis of epithelial cell ovarian cancer\(^8\). CA19-9 is a glycoprotein macromolecule that can be elevated in digestive system tumors and in patients with benign hepatobiliary and gastrointestinal diseases\(^9,10\).

Interestingly, in the present case, there were three tumor markers, including PIVKA-II, CA12-5, and CA19-9, that were elevated and then significantly decreased after decompression. The underlying mechanisms are unclear, and no previous reports have been published on this phenomenon. We propose that the elevation of ALT, AST, and TBIL levels in this patient might have resulted from the mass effect of liver compression by the giant hepatic cyst. This further led to liver function impairment, resulting in decreased levels of serum ALB and CHE as well as poor coagulation function. The giant hepatic cyst of the present patient compressed the intrahepatic bile ducts and caused obstructive jaundice. A similar case was reported by Mehtsun et al\(^11\). All of the present patient’s laboratory indexes returned to normal ranges after intra-cystic drainage, further confirming that this series of liver function changes was indeed induced by the mass effect of the giant hepatic cyst.

Yanai et al\(^5\) reported a case of simple hepatic cyst with elevated CA19-9, while cases of hepatic cysts with elevated PIVKA-II or CA12-5 have not previously been reported. We speculate that the mechanisms for the elevation of these tumor markers may be as follows: (1) A giant hepatic cyst compresses the liver, causing injury to the hepatocytes, which may lead to secretion of a large amount of PIVKA-II; (2) Some tumor-associated antigens, such as carcinoembryonic antigen (CEA), CA19-9, CA12-5, and CA15-3, are expressed on inflammatory cells\(^12,13\). We found inflammatory cells in the patient’s cystic fluid, so we conjecture that elevated serum CA19-9 and CA12-5 levels are non-specific and might be due to the effect of inflammation; and (3) Although the exfoliative cytology examination of the patient’s cystic fluid did not have a positive finding, CT scan showed no typical characteristics of serous tumor, and the tumor marker levels were significantly decreased after treatment. Therefore, the possible existence of serous tumors could not be completely ruled out because of lack of pathological examination of the cyst wall.

In summary, to the best of our knowledge, this is the first report of a giant simple hepatic cyst associated with the elevation of serum tumor marker levels of PIVKA-II, CA12-5, and CA19-9. This case revealed that an abnormal elevation of tumor markers is possible in the benign condition of giant hepatic cyst. A significant decline in the levels of these markers can serve as a tool to evaluate the effectiveness of treatment.

CONCLUSION

The present report identifies an unusual case of giant hepatic cyst with marked elevation of serum tumor marker levels of PIVKA-II, CA12-5, and CA19-9. After treatment, these three serum markers dramatically decreased to normal levels. The mechanisms for the elevation of these tumor markers may be as follows: (1) A giant hepatic cyst compresses the liver, causing injury to the hepatocytes, which may lead to secretion of a large amount of PIVKA-II; and (2) Some tumor-associated antigens, such as CEA, CA19-9, CA12-5, and CA15-3, are expressed on inflammatory cells.
Figure 1 Enhanced abdominal computed tomography before treatment. A: Arterial phase; B: Venous phase; C: Balanced phase.
REFERENCES


